472 related articles for article (PubMed ID: 17608887)
41. Prior authorization made easier.
Terry K
Med Econ; 2007 Oct; 84(20):34, 38, 40. PubMed ID: 18075056
[No Abstract] [Full Text] [Related]
42. The state and consequences of dermatology drug prices in the United States.
Albrecht J; Lebwohl M; Asgari MM; Bennett DD; Cook A; Evans CC; Green LJ; Hodge JA; Kourosh AS; Maloney ME; Howard LM; Olsen EA; Rosenberg SP; Rubin A; Stough DB; Taylor SC; Brod BA
J Am Acad Dermatol; 2016 Sep; 75(3):603-605. PubMed ID: 27423978
[No Abstract] [Full Text] [Related]
43. If foreign drug prices go up, will U.S. prices come down?
Med Health; 2003 Dec; 57(45):2-4. PubMed ID: 14723168
[No Abstract] [Full Text] [Related]
44. Medicare should bargain for lower drug prices, study says.
Med Health; 2005 Oct; 59(36):1, 3, 7. PubMed ID: 16240494
[No Abstract] [Full Text] [Related]
45. Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnesses.
Donohue JM
Psychiatr Serv; 2005 Jun; 56(6):645-7. PubMed ID: 15939937
[No Abstract] [Full Text] [Related]
46. Perspectives. What the drug benefit looks like now.
Med Health; 2003 Nov; 57(43):1, 7-8. PubMed ID: 14723115
[No Abstract] [Full Text] [Related]
47. Prescription drug benefits: cost management issues for Medicare.
Fox PD
Health Care Financ Rev; 2003; 25(2):7-21. PubMed ID: 15124374
[TBL] [Abstract][Full Text] [Related]
48. Datawatch. Rx coverage and consumer ads: a costly combo.
Bus Health; 1998 Oct; 16(10):68. PubMed ID: 10185119
[No Abstract] [Full Text] [Related]
49. Prescription drug pricing: the consumer perspective.
Searing A
N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
[No Abstract] [Full Text] [Related]
50. Help your patients become aware of the new medicare prescription drug plans.
McClellan M
Oncologist; 2005 Sep; 10(8):563-4. PubMed ID: 16177280
[No Abstract] [Full Text] [Related]
51. Strategies for acquiring affordable medications for seniors.
Morris KJ
Nurs Clin North Am; 2005 Mar; 40(1):51-62, vi. PubMed ID: 15733946
[TBL] [Abstract][Full Text] [Related]
52. Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.
Latham SR
J Leg Med; 2003 Jun; 24(2):141-73. PubMed ID: 12775406
[No Abstract] [Full Text] [Related]
53. Forecasting the future.
Tecnologica; 1999 Dec; ():1, 3-6, 14-5. PubMed ID: 10848110
[No Abstract] [Full Text] [Related]
54. The pharmaceutical industry--prices and progress.
Scherer FM
N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
[No Abstract] [Full Text] [Related]
55. Government commitment and regulation of prescription drugs.
Frank RG
Health Aff (Millwood); 2003; 22(3):46-8. PubMed ID: 12757271
[TBL] [Abstract][Full Text] [Related]
56. Study examines weapons in fight to control drug costs.
Capitation Rates Data; 2001 Apr; 6(4):39-42. PubMed ID: 11330005
[No Abstract] [Full Text] [Related]
57. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
[No Abstract] [Full Text] [Related]
58. Should drug prices be negotiated under part D of Medicare? And if so, how?
Frank RG; Newhouse JP
Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
[TBL] [Abstract][Full Text] [Related]
59. Prescription drug benefits and health status among Medicare patients.
Moldawsky R
JAMA; 2003 Oct; 290(15):1994; author reply 1994-5. PubMed ID: 14559949
[No Abstract] [Full Text] [Related]
60. Recently introduced generics helped PBM control its costs.
Manag Care; 2005 Nov; 14(11):77. PubMed ID: 16350653
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
